CRA provided testimony on behalf of plaintiff in litigation regarding a health plan’s use of MFN clauses with hospitals. CRA identified several mechanisms by which the MFN clauses were likely to reduce competition in this matter and demonstrated that they had historically harmed competitors. CRA also analyzed whether this harm to competition was offset by the procompetitive effects of MFN clauses.
An economic interpretation of Rule 23(b)(3) for antitrust classes
In this article, CRA’s Sean Durkin explains the economic incentives behind class definitions in antitrust cases and why those incentives can lead to classes...